Autisim
Autism spectrum disorder (ASD) is a neurodevelopmental disorder generally characterized by difficulty interacting and communicating with other people, repetitive behaviors, and restricted interests. Symptom severity varies greatly across those with ASD, and not all individuals will show every symptom(1).
While the exact causes of ASD remain unclear, there is strong evidence that ASD involves decreased blood flow to certain brain regions, neuroinflammation, oxidative stress, and mitochondrial dysfunction(2). Our therapies are proven to target these exact issues and may help effectively improve symptoms of ASD.
Extivita Therapies for Autism

Hyperbaric Oxygen Therapy

Neurofeedback

Nutritional IV Therapy

Supplements
Hyperbaric Oxygen Therapy for Autism
We recommend hyperbaric oxygen therapy (HBOT) for ASD due to its benefits for the immune system and blood flow(3-4). There have been several studies on the effects of HBOT for ASD, with many pointing to significant symptom improvement following HBOT(5-7).
One study found that HBOT significantly decreased markers of inflammation and resulted in improved motivation, speech, and cognitive awareness in children with ASD(5).
A more recent study also found that children with ASD improved in almost all categories of both the Autism Treatment Evaluation Checklist (ATEC) and Childhood Autism Rating Scale (CARS) following 40 sessions of HBOT(7). Although further research is necessary, preliminary evidence points to HBOT as an extremely low-risk, effective therapy for those with ASD.
Effects of HBOT on Autisim:

New Blood Vessel Formation

Increased Stem Cell Activity

Decreased Inflammation
Neurofeedback for Autism
We recommend neurofeedback therapy due to the abundance of evidence supporting its efficacy for those with ASD(8). Neurofeedback likely improves ASD symptoms by helping balance the abnormal brain wave activity that is consistently observed in those with ASD(9-11).
Neurofeedback protocols for ASD typically involve decreasing theta activity (4-7Hz) while increasing either low beta activity (12-15Hz) or mu activity (8-13Hz)(12-15). Most studies complete 40 neurofeedback sessions and have found improvements in executive functioning, verbal and nonverbal communication, sociability, repetitive behaviors, imitation, sustained attention, and more(12-15). Lastly, a recent study found that these improvements were still present 12 months after ending neurofeedback therapy(15).
IV Therapy for Autism:
We recommend our Myerβs Cocktail IV and glutathione IV for those with ASD. There is robust evidence that oxidative stress is significantly elevated in ASD(16-17). Both the Myerβs Cocktail and glutathione are powerful antioxidant IVs that effectively reduce oxidative stress and its subsequent cellular damage(18-19). Additionally, low glutathione levels have repeatedly been found in those with ASD, suggesting the need for additional sources such as glutathione infusions(16). Overall, our Myerβs Cocktail and glutathione IVs are ideal for reducing cellular dysfunction in those with ASD.
News & Research for Autism:
Hyperbaric oxygen treatment in autism spectrum disorders.
Abstract: Traditionally, hyperbaric oxygen treatment (HBOT) is indicated in several clinical disorders include decompression sickness, healing of problem wounds and arterial gas embolism. However, some investigators have used HBOT to treat individuals with autism...
Hyperbaric oxygen in the treatment of childhood autism: a randomised controlled trial.
Abstract: Promising results with hyperbaric therapy for children with autism have been reported, but most involved the use of only mild pressure with oxygen supplementation. To date, there has been no randomised, blinded trial of 100% oxygen administered at hyperbaric...
Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder
Abstract: Brain mitochondrial dysfunction has been proposed as an etiologic factor in autism spectrum disorder (ASD). Proton magnetic resonance spectroscopic imaging ((1)HMRS) and MRI were used to assess for evidence of brain mitochondrial dysfunction in...
References
- NIMHβ―Β» Autism Spectrum Disorder. https://www.nimh.nih.gov/health/topics/autism-spectrum-disorders-asd/index.shtml. Accessed 25 Mar. 2021.
- Rossignol, Daniel A., and Richard E. Frye. βEvidence Linking Oxidative Stress, Mitochondrial Dysfunction, and Inflammation in the Brain of Individuals with Autism.β Frontiers in Physiology, vol. 5, Frontiers, 2014. Frontiers, doi:10.3389/fphys.2014.00150.
- Rossignol, Daniel A., et al. βHyperbaric Oxygen Treatment in Autism Spectrum Disorders.β Medical Gas Research, vol. 2, no. 1, June 2012, p. 16. PubMed, doi:10.1186/2045-9912-2-16.
- Rossignol, Daniel A., et al. βThe Effects of Hyperbaric Oxygen Therapy on Oxidative Stress, Inflammation, and Symptoms in Children with Autism: An Open-Label Pilot Study.β BMC Pediatrics, vol. 7, Nov. 2007, p. 36. PubMed, doi:10.1186/1471-2431-7-36.
- A, Kostiukow, and Samborski W. βThe Effectiveness of Hyperbaric Oxygen Therapy (HBOT) in Children with Autism Spectrum Disorders.β Polski Merkuriusz Lekarskiβ―: Organ Polskiego Towarzystwa Lekarskiego, vol. 48, no. 283, Feb. 2020, pp. 15β18.
- Wang, Jun, et al. βResting State EEG Abnormalities in Autism Spectrum Disorders.β Journal of Neurodevelopmental Disorders, vol. 5, no. 1, Sept. 2013, p. 24. Springer Link, doi:10.1186/1866-1955-5-24.
- Stroganova, Tatiana A., et al. βAbnormal EEG Lateralization in Boys with Autism.β Clinical Neurophysiology, vol. 118, no. 8, Aug. 2007, pp. 1842β54. ScienceDirect, doi:10.1016/j.clinph.2007.05.005.
- Burnette, Courtney P., et al. βAnterior EEG Asymmetry and the Modifier Model of Autism.β Journal of Autism and Developmental Disorders, vol. 41, no. 8, Aug. 2011, pp. 1113β24. DOI.org (Crossref), doi:10.1007/s10803-010-1138-0.
- van Hoogdalem, Lothar E., et al. βThe Effectiveness of Neurofeedback Therapy as an Alternative Treatment for Autism Spectrum Disorders in Children: A Systematic Review.β Journal of Psychophysiology, Hogrefe Publishing, 2020, p. No Pagination Specified-No Pagination Specified. APA PsycNET, doi:10.1027/0269-8803/a000265.
- Kouijzer, Mirjam E. J., et al. βNeurofeedback Treatment in Autism. Preliminary Findings in Behavioral, Cognitive, and Neurophysiological Functioning.β Research in Autism Spectrum Disorders, vol. 4, no. 3, July 2010, pp. 386β99. ScienceDirect, doi:10.1016/j.rasd.2009.10.007.
- Kouijzer, Mirjam E. J., et al. βNeurofeedback Improves Executive Functioning in Children with Autism Spectrum Disorders.β Research in Autism Spectrum Disorders, vol. 3, no. 1, Jan. 2009, pp. 145β62. ScienceDirect, doi:10.1016/j.rasd.2008.05.001.
- Pineda, J. A., et al. βPositive Behavioral and Electrophysiological Changes Following Neurofeedback Training in Children with Autism.β Research in Autism Spectrum Disorders, vol. 2, no. 3, July 2008, pp. 557β81. ScienceDirect, doi:10.1016/j.rasd.2007.12.003.
- Datko, Michael, et al. βPositive Effects of Neurofeedback on Autism Symptoms Correlate with Brain Activation during Imitation and Observation.β European Journal of Neuroscience, vol. 47, no. 6, 2018, pp. 579β91. Wiley Online Library, doi:https://doi.org/10.1111/ejn.13551.
- Kouijzer, Mirjam E. J., et al. βLong-Term Effects of Neurofeedback Treatment in Autism.β Research in Autism Spectrum Disorders, vol. 3, no. 2, Apr. 2009, pp. 496β501. ScienceDirect, doi:10.1016/j.rasd.2008.10.003.
- Adams, James B., et al. βNutritional and Metabolic Status of Children with Autism vs. Neurotypical Children, and the Association with Autism Severity.β Nutrition & Metabolism, vol. 8, no. 1, June 2011, p. 34. PubMed, doi:10.1186/1743-7075-8-34.
- Essa, M. M., et al. βExcitotoxicity in the Pathogenesis of Autism.β Neurotoxicity Research, vol. 23, no. 4, May 2013, pp. 393β400. PubMed, doi:10.1007/s12640-012-9354-3.
- Carr, Anitra C., and Silvia Maggini. βVitamin C and Immune Function.β Nutrients, vol. 9, no. 11, Nov. 2017. PubMed Central, doi:10.3390/nu9111211.
- Forman, Henry Jay, et al. βGlutathione: Overview of Its Protective Roles, Measurement, and Biosynthesis.β Molecular Aspects of Medicine, vol. 30, no. 1β2, Apr. 2009, pp. 1β12. PubMed, doi:10.1016/j.mam.2008.08.006.
